Merck Sees Promise for Mass Spec-Based Protein Biomarker Pipeline in Drug Development

"It might not necessarily be an in vitro diagnostic that's going to hit the market," a Merck researcher said of the company's mass spec-based biomarker assays, "but it can certainly help us make decisions as we move a drug to market."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.